Patient P-02176

Synthetic patientMETA-24 · Day 151 · 65–74 · M · baseline S14Open companion preview

Therapy response

Stable

Tolerance

Improving

GI state

Improving

Inflammatory state

Improving

Nutritional resilience

Stable

Discontinuation risk

54%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S14
Day 47 NP-02 recommended — Dietary Support Protocol NP-02
Day 48 Patient accepted — Started NP-02 in the companion
Day 58 GI symptom burden −25% vs expected — Dietary Support Protocol NP-02
Day 64 Tolerance state changed — Unstable → Improving
Day 74 GI-04 recommended — GI Support Protocol GI-04
Day 75 Patient accepted — Started GI-04 in the companion
Day 83 GI symptom burden −32% vs expected — GI Support Protocol GI-04
Day 89 Tolerance state changed — Unstable → Improving
Day 100 Trajectory diverged from prediction — Observed response fell below the model's expected path.

What changed?

Trajectory began diverging from predicted response on Day 100.

Primary contributors, last 14 days

GI instability-8
Inflammatory activity-7
Toxicity-4
Nutritional resilience-3

What helped?

Dietary Support Protocol NP-02Day 47
Result: symptom burden −25%
GI Support Protocol GI-04Day 74
Result: symptom burden −32%

LIFE OS recommendation

Supportive Compound SC-12

53%

probability of meaningful tolerance improvement

284 similar trajectories
69% showed improvement
median effect visible after 6 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 28/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Mucosal barrier integrity ↓70
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- WearableSleep 6.0 h, below personal baseline
Autonomic recovery ↑45
- WearableResting HR 73 bpm
- WearableShort sleep window
Inflammatory signalling ↓20
- MicrobiomeBacteroides fragilis expansion

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 3 · butyrate capacity 28/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 44 ms
Sleep: 5.7 h
Steps: 6,524
Resting HR: 76 bpm

Daily log: GI score 35, nutritional resilience 50, adherence 52.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Keep meals regular; three to four moderate portions spaced through the day
Include a cooked vegetable portion with each main meal
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Log the daily check-in; one line is enough
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
No additional supplements this week
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02051	49%	S14	GI-04	improved	45
P-02674	48%	S02	NP-02	improved	48
P-02328	46%	S14	GI-04	improved	42
P-02108	44%	S14	GI-04	improved	43
P-02255	44%	S14	GI-04	improved	43
P-02410	43%	S01	GI-04	improved	55
P-02504	43%	S14	GI-04	improved	52
P-02002	42%	S14	GI-04	improved	47
P-02103	40%	S14	GI-04	improved	46
P-02216	40%	S11	GI-04	improved	53
P-02125	38%	S14	GI-04	improved	55
P-02321	38%	S17	GI-04	improved	54